Femasys (FEMY) Total Debt to Capital

Femasys Inc. (FEMY) relies on its own US-based development centers and the mass production of high-demand, patent-protected diagnostic systems. The business's success is based on physician recognition of non-invasive methods and the level of insurance reimbursements for FemaSeed. The market capitalization trend on GURU.Markets is 1.17, while the company remains largely independent of broader economic conditions, focusing instead on the commercialization of innovations and clinical trials.

This metric measures the proportion of borrowed funds relative to equity, determining the degree of financial dependence and the risk of bankruptcy during liquidity shortages. By analyzing the financial leverage ratio (total debt-to-equity), an investor can assess the ability of Femasys Inc. (FEMY) to finance the implementation of infertility diagnostic tools and physician marketing without imposing a critical debt burden on the issuer's balance sheet.